Managed access to ianalumab for serious conditions
Treatments studied
Part of Blood & lymphatic, Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This program provides access to an experimental medicine called ianalumab for people with serious or life-threatening conditions who have no other treatment options and cannot join a clinical trial. Your doctor must request this medicine for you, and the company (Novartis) will review each request individually.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your doctor must ask for this medicine for you (you can't request it yourself).
- You have a serious or life-threatening condition for which no other good treatment options are left.
- You cannot join or stay in a clinical trial for your condition.
- Your doctor and the company must agree that the possible benefits of the medicine outweigh the risks for you.
- The medicine must be allowed in your country, and getting it must not interfere with ongoing clinical trials.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program provides access to an experimental medicine called alpelisib (also known as BYL719) for people with serious conditions who have no other treatment options and cannot participate in clinical trials. If a licensed doctor requests it, and you meet the criteria, you may be able to receive this medicine through a managed access program.
This program provides crizanlizumab, a medicine that may help reduce pain crises in sickle cell disease, to patients who have no other treatment options and cannot join a clinical trial. It is a special access program for individual patients.
This program provides access to an investigational medication called eltrombopag for people with serious or life-threatening conditions who have no other good treatment options. It is only available through a doctor's formal request and is not part of a clinical trial.
This program lets doctors request an unapproved drug for patients with serious, life-threatening diseases when no other good options exist. It's a way to get the medicine outside of a clinical trial.
This program provides access to atrasentan for people with serious or life-threatening conditions who have no other treatment options and cannot join a clinical trial.
This trial gives people with serious diseases access to a special cell therapy (a treatment made from your own immune cells) when they have no other options. It's a 'compassionate use' program, meaning the drug is available outside of a clinical trial if you meet certain conditions.
Hear when a new Primary Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.